The News of Us
  • Home
  • Business
  • Politics
  • Science and Technology
  • Health
  • Subscribe Us
No Result
View All Result
The News of Us
  • Home
  • Business
  • Politics
  • Science and Technology
  • Health
  • Subscribe Us
No Result
View All Result
The News of Us
No Result
View All Result

Single Injection, Broad Protection

Vaccine generates robust immune responses against SARS-CoV-2 variants.

In the three months since Johnson & Johnson’s COVID-19 vaccine was granted an emergency use authorization from the U.S. Food and Drug Administration, more than 10 million Americans have received the vaccine, according to the U.S. Centers for Disease Control and Prevention.

The single-dose viral vector vaccine, developed in collaboration with Dan Barouch, the William Bosworth Castle Professor of Medicine at Harvard Medical School and Beth Israel Deaconess Medical Center, was authorized for use based on clinical trial data showing strong clinical efficacy against symptomatic COVID-19 in the United States, Latin America, and South Africa.

In a new study published as an accelerated article in Nature, Barouch, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess, and colleagues report on the antibody and cellular immune responses in a group of 20 participants generated by the Ad26.COV2.S vaccine against both the original SARS-CoV-2 viral strain and variants of concern.

The team found that the J&J vaccine-induced immune responses against all viral variants.

“The concern is whether SARS-CoV-2 variants may reduce the efficacy of current vaccines that were designed to protect against the original SARS-CoV-2 strain at the beginning of the pandemic,” said Barouch, senior author of the study.

“These findings, therefore, have important implications for vaccine protection against SARS-CoV-2 variants of concern.”

To explore the immune response triggered by the vaccine, Barouch and colleagues administered one or two doses to the 20 volunteers, ages 18 to 55.

All of the individuals in this small group were part of a larger multicenter, randomized, double-blind, placebo-controlled phase 1/2a study to evaluate the vaccine at various doses and schedules.

The researchers then used multiple methods to assess antibody and cellular immune responses against the original viral strain (WA1/2020) and against several viral variants first identified in South Africa (B.1.351 or beta), the United Kingdom (B.1.1.7 or alpha), Brazil (P.1 or gamma) and the U.S. (CAL.20C or epsilon).

The analysis showed that, when compared with antibody responses against the original viral strain, participants had dropped in levels of neutralizing antibodies against the beta and gamma variants.

However, two other protective responses—non-neutralizing antibody responses and T cell responses—were either minimally impacted or not impacted by SARS-CoV-2 variants.

In other words, the participants’ immune systems retained some of their ability to counter the viral variants even when their levels of neutralizing antibodies dropped.

These findings may help explain the vaccine’s efficacy, demonstrated in phase 3 clinical trials, protection that likely stems from the presence of non-neutralizing antibodies and/or T cell responses, the team said.

The results from the phase 3 trials, published in The New England Journal of Medicine, showed that the vaccine offered strong protection against symptomatic COVID-19 in South Africa and in Brazil where most sequenced COVID-19 cases were caused by variants.

“Although the mechanistic correlates of protection for COVID-19 are not yet known, the vaccine’s robust protective efficacy in these regions raises the possibility that non-neutralizing antibodies and/or T cell responses may also contribute to the protection,” said Barouch, who is also a member of the Ragon Institute of MGH, MIT, and Harvard.

“Alternatively, it is possible that low levels of neutralizing antibodies are sufficient for protection against COVID-19.”

Source: HMS

[Read More…]

Previous Post

Dollar hovers near one-month high with market frozen before Fed test

Next Post

Two COVID-19 vaccines show safety, strong immunity in infant model

Related Posts

News

The Masked Singer Season 7 Just Delivered Its Most Crushing Elimination Yet

News

Blood, bullet holes, shell casings: the aftermath of Brooklyn subway rampage

News

Heartbreaking notes posted by students on Sunset Park school windows after Brooklyn subway shooting

News

After latest bloodbath, time is running out for Hochul and Adams to save NYC

News

After Internet Wonders If Josh Brolin Will Be In Dune 2, The Actor Clarifies The ‘Ridiculous’ Situation

News

‘RHONJ’ Recap: Teresa Giudice Threatens To ‘Beat’ Margaret Josephs During Nashville Fight

Next Post

Two COVID-19 vaccines show safety, strong immunity in infant model

Follow us for latest Business News | Political News | Science & Technology News | Health News.

Subscribe Us

By clicking subscribe, I authorize: (1) The News Of Us to use and share my information in accordance with its Terms of Service and Privacy Policy, and (2) The News Of Us or third-party companies, including The News Of Us’s business partners, to contact me by email with offers for goods and services at the email address provided. Please note that the information you have provided to us may be supplemented with additional information obtained from other sources.
Loading

© 2021 The News of Us, - All Rights Reserved.

  • Subscribe Us
  • Contact Us
  • Unsubscribe
  • Privacy Policy
  • Terms Of Service
No Result
View All Result
  • Home
  • Business
  • Politics
  • Science and Technology
  • Health
  • Subscribe Us

© 2021 The News of Us, - All Rights Reserved.